Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 50,362 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Malignancies Clear all
Terminated Phase 2 Interventional Results available

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

NCT01934894
View directory record Official record
Conditions
Metastatic Breast Cancer With Intracranial Metastases
Interventions
cabazitaxel, lapatinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 30, 2026, 11:05 AM EDT
Completed Phase 1Phase 2 Interventional

Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes

NCT00093366
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
etanercept, arsenic trioxide
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 30, 2026, 11:05 AM EDT
Withdrawn Phase 2 Interventional

Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

NCT00485966
View directory record Official record
Conditions
B-Cell Chronic Lymphocytic Leukemia
Interventions
CX-3543
Drug
Lead sponsor
Cylene Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Scottsdale, Arizona • Beverly Hills, California • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2008 · Synced Oct 30, 2026, 11:05 AM EDT
Recruiting Phase 2 Interventional

Fluorescent Intra-operative Tumor Margin Examination

NCT04719156
View directory record Official record
Conditions
Sarcoma
Interventions
Indocyanine green solution administered at 2.0mg/kg., Stryker SPY-PHI Imaging Device
Drug · Device
Lead sponsor
Kurt Weiss
Other
Eligibility
18 Years to 100 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 30, 2026, 11:05 AM EDT
Active, not recruiting Phase 2 Interventional

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

NCT03092856
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions
Anti-OX40 Antibody PF-04518600, Axitinib, Laboratory Biomarker Analysis, Placebo
Biological · Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Newport Beach, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 30, 2026, 11:05 AM EDT
Suspended Phase 1 Interventional

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

NCT05400122
View directory record Official record
Conditions
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
Interventions
Vactosertib, Fludarabine Phosphate, Cyclophosphamide, IL-2, Natural Killer Cells
Drug
Lead sponsor
David Wald
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 30, 2026, 11:05 AM EDT
Recruiting No phase listed Observational

BostonGene-Integrated Genomic Registry (BIGR)

NCT04991922
View directory record Official record
Conditions
Malignancy
Interventions
Not listed
Lead sponsor
BostonGene
Industry
Eligibility
18 Years and older
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 11:05 AM EDT
Terminated Not applicable Interventional

Comparison of Barium Enema, Computed Tomographic Colonography, and Colonoscopy in Detecting Colon Cancer

NCT00016029
View directory record Official record
Conditions
Colorectal Cancer
Interventions
screening questionnaire administration, barium enema injection, computed tomography, computed tomography colonography, diagnostic colonoscopy, screening colonoscopy
Other · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
14
States / cities
La Jolla, California • San Francisco, California • Vero Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 30, 2026, 11:05 AM EDT
Terminated Not applicable Interventional Results available

Evaluation of t-RFA and RF-TVA Prior to/Following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s)

NCT02225223
View directory record Official record
Conditions
Metastatic Lesions in Vertebral Bodies
Interventions
STAR™ Tumor Ablation System, StabiliT® Vertebral Augmentation System
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Torrance, California • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 30, 2026, 11:05 AM EDT
Terminated Phase 1 Interventional

Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

NCT03301896
View directory record Official record
Conditions
Solid Tumors
Interventions
LHC165, PDR001
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 30, 2026, 11:05 AM EDT
Recruiting Phase 2 Interventional

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

NCT02133196
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinoma
Interventions
Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 11:05 AM EDT
Completed Not applicable Interventional Results available

MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum

NCT01719562
View directory record Official record
Conditions
Cardiac Toxicity, Malignant Neoplasm, Breast Cancer
Interventions
Magnetic resonance imaging, Physical Activity, Healthy Living, Cardiopulmonary Exercise Testing (CPET), Questionnaire Administration
Procedure · Other · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 30, 2026, 11:05 AM EDT
Active, not recruiting Phase 1 Interventional

Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer

NCT04311762
View directory record Official record
Conditions
Lung Cancer Metastatic
Interventions
cisplatin
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 30, 2026, 11:05 AM EDT
Completed No phase listed Observational

Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear Test

NCT02734303
View directory record Official record
Conditions
Cancers
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
70 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Oct 30, 2026, 11:05 AM EDT
Completed Not applicable Interventional

Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility

NCT02133703
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
Enhanced Internet DA, Internet DA, Enhanced Print DA, Print DA, Inconclusive Results DA
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 30, 2026, 11:05 AM EDT
Completed Not applicable Interventional

ASk Questions in GYnecologic Oncology (ASQ-GYO)

NCT06339827
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Gestational Trophoblastic Disease
Interventions
Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List
Behavioral
Lead sponsor
Ira Winer
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 30, 2026, 11:05 AM EDT
Completed Phase 2 Interventional Results available

Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer

NCT03747042
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Letrozole
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 30, 2026, 11:05 AM EDT
Terminated Phase 2 Interventional Results available

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

NCT03140670
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
RUCAPARIB
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 30, 2026, 11:05 AM EDT
Completed Phase 1 Interventional

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

NCT02857270
View directory record Official record
Conditions
Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
Interventions
LY3214996, Midazolam, Abemaciclib, Nab-paclitaxel, Gemcitabine, Encorafenib, Cetuximab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Sarasota, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 30, 2026, 11:05 AM EDT
Not listed Phase 2 Interventional

Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction

NCT02913573
View directory record Official record
Conditions
Breast Neoplasm
Interventions
Ultrasound, 0.25% bupivacaine
Device · Drug
Lead sponsor
Huntington Memorial Hospital
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 30, 2026, 11:05 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Molecular Epidemiology of Acute Myelogenous Leukemia

NCT00502983
View directory record Official record
Conditions
Leukemia
Interventions
Interview
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
519 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 30, 2026, 11:05 AM EDT
Completed Not applicable Interventional

Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma

NCT00590941
View directory record Official record
Conditions
Lymphoma, Diffuse Large Cell
Interventions
Blood draw
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 30, 2026, 11:05 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma

NCT03600441
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Abexinostat
Drug
Lead sponsor
Xynomic Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
9
States / cities
Park Ridge, Illinois • Louisville, Kentucky • Lake Success, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 30, 2026, 11:05 AM EDT
Recruiting Phase 1 Interventional

D2C7-IT + 2141-V11 Combination Post-resection in rGBM

NCT06455605
View directory record Official record
Conditions
Recurrent Glioblastoma IDH Wildtype
Interventions
D2C7-IT, 2141 V11
Drug
Lead sponsor
Darell Bigner
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 11:05 AM EDT